- Lexaria’s 2022 R&D programs are set to include research on hormone replacement, dementia, rheumatoid disease, and diabetes, among other conditions
- The program builds on findings from 2021 studies which supported significant advances in the oral nicotine, heart disease, and antiviral markets
- The 2022 program will continue to focus on the company’s patented DehydraTECH drug delivery platform
- Lexaria will also be conducting pharmacokinetic and efficacy modeling studies in animals to evaluate DehydraTECH’s overall efficiency
In 2021,
Lexaria Bioscience (NASDAQ: LEXX) raised approximately $15 million in funding. The money allowed for active work programs throughout the year while supporting significant advances in oral nicotine, heart disease, and antiviral research. Lexaria plans to take the findings from these 2021 studies and improve them with the 2022 R&D programs, which include hormone replacement, dementia, diabetes, and rheumatoid disease (
https://cnw.fm/yWe72).
While making the announcement, Chris Bunka, the Chief Executive Officer (“CEO”) of Lexaria, noted, “Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for investigation of…
Read More>>
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at
https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2)
CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit
https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published:
http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW?
Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the
InvestorBrandNetwork.